Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UDCA Bioenergetics in Parkinson's Disease
NCT02967250Phase 1Completed
- Sponsor
- University of Minnesota
- Start
- Apr 2020
- Primary completion
- Feb 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ursodeoxycholic acid in Parkinson's disease (PD), sponsored by University of Minnesota. Primary endpoint: Change in ATP concentration at 6 weeks. Started Apr 2020; status: completed.
02
Drugs
ursodeoxycholic acid
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02967250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02967250.